Literature DB >> 20051426

Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1.

Misha Koshelev1, Satyam Sarma, Roger E Price, Xander H T Wehrens, Thomas A Cooper.   

Abstract

Myotonic dystrophy type 1 (DM1) is caused by a CTG expansion within the 3'-untranslated region of the DMPK gene. The predominant mechanism of pathogenesis is a toxic gain of function of CUG repeat containing RNA transcribed from the expanded allele. The molecular mechanisms by which the RNA containing expanded repeats produce pathogenic effects include: sequestration of muscleblind-like 1 (MBNL1) protein and up-regulation of CUG binding protein 1 (CUGBP1). MBNL1 and CUGBP1 are RNA binding proteins that regulate alternative splicing transitions during development. Altered functions of these proteins in DM1 lead to misregulated splicing of their target genes, resulting in several features of the disease. The role of MBNL1 depletion in DM1 is well established through a mouse knock-out model that reproduces many disease features. Here we directly test the hypothesis that CUGBP1 up-regulation also contributes to manifestations of DM1. Using tetracycline-inducible CUGBP1 and heart-specific reverse tetracycline trans-activator transgenes, we expressed human CUGBP1 in adult mouse heart. Our results demonstrate that up-regulation of CUGBP1 is sufficient to reproduce molecular, histopathological and functional changes observed in a previously described DM1 mouse model that expresses expanded CUG RNA repeats as well as in individuals with DM1. These results strongly support a role for CUGBP1 up-regulation in DM1 pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20051426      PMCID: PMC2830830          DOI: 10.1093/hmg/ddp570

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  35 in total

1.  Codon optimization markedly improves doxycycline regulated gene expression in the mouse heart.

Authors:  M L Valencik; J A McDonald
Journal:  Transgenic Res       Date:  2001-06       Impact factor: 2.788

2.  Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein.

Authors:  D S Sohal; M Nghiem; M A Crackower; S A Witt; T R Kimball; K M Tymitz; J M Penninger; J D Molkentin
Journal:  Circ Res       Date:  2001-07-06       Impact factor: 17.367

3.  The CELF family of RNA binding proteins is implicated in cell-specific and developmentally regulated alternative splicing.

Authors:  A N Ladd; N Charlet; T A Cooper
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

4.  Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy.

Authors:  J W Miller; C R Urbinati; P Teng-Umnuay; M G Stenberg; B J Byrne; C A Thornton; M S Swanson
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

5.  RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1.

Authors:  N A Timchenko; Z J Cai; A L Welm; S Reddy; T Ashizawa; L T Timchenko
Journal:  J Biol Chem       Date:  2000-12-21       Impact factor: 5.157

6.  Risk of arrhythmia in type I myotonic dystrophy: the role of clinical and genetic variables.

Authors:  P Cudia; P Bernasconi; R Chiodelli; F Mangiola; F Bellocci; A Dello Russo; C Angelini; V Romeo; P Melacini; L Politano; A Palladino; G Nigro; G Siciliano; M Falorni; M G Bongiorni; C Falcone; R Mantegazza; L Morandi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-02-22       Impact factor: 10.154

7.  A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart.

Authors:  Auinash Kalsotra; Xinshu Xiao; Amanda J Ward; John C Castle; Jason M Johnson; Christopher B Burge; Thomas A Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

8.  Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice.

Authors:  Mihail G Chelu; Satyam Sarma; Subeena Sood; Sufen Wang; Ralph J van Oort; Darlene G Skapura; Na Li; Marco Santonastasi; Frank Ulrich Müller; Wilhelm Schmitz; Ulrich Schotten; Mark E Anderson; Miguel Valderrábano; Dobromir Dobrev; Xander H T Wehrens
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

9.  Ambulatory ECG recording in mice.

Authors:  Mark D McCauley; Xander H T Wehrens
Journal:  J Vis Exp       Date:  2010-05-27       Impact factor: 1.355

Review 10.  RNA and disease.

Authors:  Thomas A Cooper; Lili Wan; Gideon Dreyfuss
Journal:  Cell       Date:  2009-02-20       Impact factor: 41.582

View more
  78 in total

1.  Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of Ca(V)1.1 calcium channel.

Authors:  Zhen Zhi Tang; Viktor Yarotskyy; Lan Wei; Krzysztof Sobczak; Masayuki Nakamori; Katy Eichinger; Richard T Moxley; Robert T Dirksen; Charles A Thornton
Journal:  Hum Mol Genet       Date:  2011-12-02       Impact factor: 6.150

Review 2.  Role of noncoding RNAs in trinucleotide repeat neurodegenerative disorders.

Authors:  Huiping Tan; Zihui Xu; Peng Jin
Journal:  Exp Neurol       Date:  2012-01-27       Impact factor: 5.330

Review 3.  Myotonic dystrophy mouse models: towards rational therapy development.

Authors:  Mário Gomes-Pereira; Thomas A Cooper; Geneviève Gourdon
Journal:  Trends Mol Med       Date:  2011-07-02       Impact factor: 11.951

Review 4.  Global impact of RNA splicing on transcriptome remodeling in the heart.

Authors:  Chen Gao; Yibin Wang
Journal:  J Zhejiang Univ Sci B       Date:  2012-08       Impact factor: 3.066

Review 5.  The muscular dystrophies: distinct pathogenic mechanisms invite novel therapeutic approaches.

Authors:  Zarife Sahenk; Jerry R Mendell
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

Review 6.  CELFish ways to modulate mRNA decay.

Authors:  Irina Vlasova-St Louis; Alexa M Dickson; Paul R Bohjanen; Carol J Wilusz
Journal:  Biochim Biophys Acta       Date:  2013-01-15

7.  Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.

Authors:  Ramesh S Yadava; Qing Yu; Mahua Mandal; Frank Rigo; C Frank Bennett; Mani S Mahadevan
Journal:  Hum Mol Genet       Date:  2020-06-03       Impact factor: 6.150

Review 8.  Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy.

Authors:  Zhihua Gao; Thomas A Cooper
Journal:  Hum Gene Ther       Date:  2013-01-30       Impact factor: 5.695

Review 9.  CUG-BP, Elav-like family (CELF)-mediated alternative splicing regulation in the brain during health and disease.

Authors:  Andrea N Ladd
Journal:  Mol Cell Neurosci       Date:  2012-12-14       Impact factor: 4.314

10.  RBFox1-mediated RNA splicing regulates cardiac hypertrophy and heart failure.

Authors:  Chen Gao; Shuxun Ren; Jae-Hyung Lee; Jinsong Qiu; Douglas J Chapski; Christoph D Rau; Yu Zhou; Maha Abdellatif; Astushi Nakano; Thomas M Vondriska; Xinshu Xiao; Xiang-Dong Fu; Jau-Nian Chen; Yibin Wang
Journal:  J Clin Invest       Date:  2015-11-30       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.